We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Process for Referring Potentially Risky Pediatric Clinical Trials Published
Process for Referring Potentially Risky Pediatric Clinical Trials Published
January 15, 2007
The process for institutional review boards (IRBs) to refer potentially high-risk clinical trials involving children to the FDA for special review is laid out in detail in a new guidance document.
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor